Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease
- Yansheng Du, Zhi-zhong Ma, S. Paul
- Biology, ChemistryProceedings of the National Academy of Sciences…
- 27 November 2001
The results suggest that minocycline blocks MPTP neurotoxicity in vivo by indirectly inhibiting MPTP/MPP+-induced glial iNOS expression and/or directly inhibiting NO-induced neurotoxicity, most likely by inhibiting the phosphorylation of p38 MAPK.
Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
- A. Porter, J. Sauer, C. Felder
- Biology, ChemistryThe Journal of pharmacology and experimental…
- 1 June 2002
Virodhamine produced hypothermia in the mouse and acted as an antagonist in the presence of anandamide both in vivo and in vitro, adding a new form of regulation to the endocannabinoid system.
Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex
Comparing the ability of five systemically administered selective serotonin uptake inhibitors to increase acutely the extracellular concentrations of serotonin, norepinephrine and dopamine in rat prefrontal cortex suggests that fluoxetine is an atypical SSRI.
A novel augmentation strategy for treating resistant major depression.
Olanzapine plus fluoxetine demonstrated superior efficacy for treating resistant depression compared to either agent alone.
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
The observed improvements in ADAS-Cog and CIBIC+ following treatment with xanomeline provide the first evidence, from a large-scale, placebo-controlled clinical trial, that a direct-acting muscarinic receptor agonist can improve cognitive function in patients with AD.
Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication.
Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat